Aberdeen Group plc Buys 692,247 Shares of InspireMD, Inc. $NSPR

Aberdeen Group plc grew its stake in shares of InspireMD, Inc. (NYSE:NSPR) by 27.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,173,364 shares of the company’s stock after buying an additional 692,247 shares during the quarter. Aberdeen Group plc owned 7.49% of InspireMD worth $5,649,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of NSPR. Creative Planning purchased a new stake in shares of InspireMD during the second quarter worth about $44,000. Uniting Wealth Partners LLC purchased a new stake in shares of InspireMD during the third quarter worth about $51,000. Citadel Advisors LLC boosted its holdings in shares of InspireMD by 45.0% during the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock worth $91,000 after purchasing an additional 11,778 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of InspireMD by 28.9% during the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after purchasing an additional 10,000 shares during the period. Finally, Vestia Personal Wealth Advisors boosted its holdings in shares of InspireMD by 135.7% during the third quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock worth $102,000 after purchasing an additional 24,425 shares during the period. 44.78% of the stock is owned by institutional investors.

InspireMD Stock Down 1.4%

Shares of NYSE NSPR opened at $1.37 on Thursday. InspireMD, Inc. has a twelve month low of $1.32 and a twelve month high of $2.93. The firm has a market cap of $64.12 million, a P/E ratio of -1.83 and a beta of 0.95. The company has a 50 day moving average of $1.69 and a 200 day moving average of $1.90.

Insiders Place Their Bets

In other InspireMD news, insider Shane Thomas Gleason sold 17,593 shares of InspireMD stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $1.62, for a total value of $28,500.66. Following the completion of the sale, the insider owned 1,174,664 shares of the company’s stock, valued at approximately $1,902,955.68. The trade was a 1.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 61,194 shares of company stock valued at $99,188. 34.06% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Maxim Group assumed coverage on shares of InspireMD in a report on Monday, February 2nd. They set a “buy” rating and a $6.00 target price for the company. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Finally, Lake Street Capital reiterated a “buy” rating on shares of InspireMD in a report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $5.00.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.